<DOC>
	<DOCNO>NCT00549978</DOCNO>
	<brief_summary>investigate safety pharmacokinetics , healthy adult male subject</brief_summary>
	<brief_title>Safety Pharmacokinetics Probucol Cilostazol</brief_title>
	<detailed_description>Safety Pharmacokinetics Probucol Cilostazol co-administered Health Subjects</detailed_description>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Korean Gender : Male Age : Over 20 Under 40years , time informed consent body weight : BMI 19.0 Under 25.0 Subjects meet follow criterion time screen examination Subjects give write informed consent prior participation study Subjects reliable willing make available duration study follow study protocol History clinical evidence significant respiratory , cardiovascular , renal , gastrointestinal , hepatic , endocrine , hematologic , neurologic , psychiatric , chronic disease , alcoholism , drug abuse Present previous significant drug allergy prescription counter medication Blood collection exceed 200ml within 4 week , 400ml within 12 week , 1200ml within one year prior schedule study drug administration Body weight : 50Kg</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Safety Pharmacokinetics healthy subject</keyword>
</DOC>